Predictive Value of Embryonic Testing

Reproductive Medicine Associates of New Jersey237 enrolled

Overview

The primary objective of this study is to determine the predictive value of preimplantation genetic screening (PGS) as a marker of embryonic competence. Secondary objectives are to define the related or independent predictive values of other proposed markers of embryonic and maternal reproductive competence in assisted reproductive technology (ART) cycles.

Patients participating in the study will undergo a routine in vitro fertilization cycle. Trophectoderm biopsy will be performed on all blastocysts however biopsy samples will not be analyzed till the clinical outcome has been determined. The single, morphologically best embryo available will be selected for transfer. All clinical and laboratory care is identical to that of which subjects would receive if they were not participating in the study. This includes all pretreatment screening, in-cycle treatment, embryology procedures, single embryo transfer, pregnancy testing, and pregnancy follow-up (if pregnancy occurs).

Study Type

OBSERVATIONAL

Enrollment

237

Conditions

Infertility

Interventions

Preimplantation Genetic Testing-AneuploidyGENETIC

trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Couples electing embryonic aneuploidy screening (PGS) 2. Couples electing single embryo transfer Exclusion Criteria: 1. Any prior failed IVF cycle 2. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid 3. Diagnosis of chronic endometritis 4. Maximum day 3 FSH level of 12 or higher 5. Anti-mullerian hormone level less than 0.5 g/mL, tested within previous year 6. Total basal antral follicle count less than 8 follicles 7. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable) 8. BMI \<18.5 or \> 35 9. Personal history of recurrent pregnancy loss (two or more pregnancy losses) 10. Use of oocyte donation 11. Use of gestational carrier 12. Medical condition predisposing patient to high risk pregnancy 13. Use of surgical procedures to obtain sperm 14. Presence of hydrosalpinges that communicate with endometrial cavity 15. Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation 16. Single gene disorder or chromosomal rearrangement requiring a more detailed embryonic genetic analysis

Locations (4)

Reproductive Medicine Associates of Florida

Lake Mary, Florida, United States

Reproductive Medicine Associates of New Jersey

Basking Ridge, New Jersey, United States

Reproductive Medicine Associates of Pennsylvania

Allentown, Pennsylvania, United States

Reproductive Medicine Associates of Philadelphia

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Predictive Value of Aneuploidy Screening

Determine confidence intervals that a euploid embryo will implant, an aneuploid embryo will not implant, and the likelihood of mosaic and segmental aneuploid embryos implanting and describe their outcomes.

Time frame: approximately 1 month post clinical outcome

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.